Simultaneous treatment of moderate-to-severe horizontal frontalis lines, glabellar lines, and lateral canthal lines with onabotulinumtoxinA, from the subject’s perspective: Patient-reported satisfaction and impact outcomes from a phase 3 double-blind study

Purpose: Safety and efficacy of onabotulinumtoxinA (onabotA) for simultaneous treatment of horizontal forehead lines (FHL) and glabellar complex and simultaneous treatment of upper facial lines (UFL) were assessed in a 12-month, placebo-controlled study. The primary end point was met. Secondary efficacy results (patient-reported satisfaction and treatment impacts) are presented here.